Volume 16, Issue 2 (March 2014) 16, 268–269; 10.4103/1008-682X.122364
Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo
Richard G. Pestell1, Zuoren Yu2
1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 2Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China
Correspondence: Dr. RG Pestell or Dr. Z Yu
07 January 2014
Abstract |
Hyperactive androgen receptor (AR) activity remains a key determinant of the onset and progression of prostate cancer and resistance to current therapies. The mechanisms governing castrate resistant prostate cancer are poorly understood, but defi ning these molecular events is essential in order to impact deaths from prostate cancer. Yang et al. demonstrate that two lnc-RNAs known to be overexpressed in therapy resistant prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bound to the AR to enhance ligand-dependent and ligand-independent AR gene expression and proliferation of prostate cancer cells.1 Th e sequence of these interactions involved the binding of PRNCR1 to the acetylated AR and a subsequent association of DOT1L, which was required for the sequential recruitment of the lncRNA PCGEM1 to the AR amino terminus, which in turn was methylated by DOT1L.
Full Text |
PDF |
中文摘要 |
|
|
Browse: 2506 |
|